A RANDOMIZED STUDY OF INTRAVESICAL MITOMYCIN-C, BACILLUS-CALMETTE-GUERIN TICE AND BACILLUS-CALMETTE-GUERIN RIVM TREATMENT IN PTA-PT1 PAPILLARY CARCINOMA AND CARCINOMA IN-SITU OF THE BLADDER

Results of a randomized prospective study are reported in which mitomy cin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ. The followup (or time in study) varied fr om 2 to 81 months (mean 36 months). After complete transurethral resec tion of all visible tumors the patients were treated with 30 mg. mitom ycin C once a week for 4 consecutive weeks and thereafter every month for a total of 6 months, and 5 x 10(8) colony-forming units Tice BCG o r RIVM-BCG once a week for 6 consecutive weeks. For papillary tumors m itomycin C and RIVM-BCG treatments were equally effective (p = 0.53), and mitomycin C was more effective than Tice BCG therapy (p = 0.01).